Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycyrrhizae decoction is a traditional Chinese medicine (TCM) preparation derived from the roots and rhizomes of *Glycyrrhiza uralensis* (licorice). It was developed and clinically evaluated by the First Affiliated Hospital of Henan University of Chinese Medicine (formerly Henan College of TCM) for the treatment of recurrent oral ulcers in patients with HIV/AIDS. The decoction's therapeutic profile is driven by its primary active component, glycyrrhizic acid (glycyrrhizin), which acts as an antagonist of High mobility group box 1 (HMGB1) and an inhibitor of 11-beta-hydroxysteroid dehydrogenase. These mechanisms contribute to potent anti-inflammatory and immunomodulatory effects, including the suppression of pro-inflammatory cytokines such as TNF-alpha and interleukins. By modulating the local immune environment and promoting mucosal repair, glycyrrhizae decoction helps reduce the pain, duration, and recurrence of oral lesions in immunocompromised individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glycyrrhizae decoction.